Form 4: LENZ Director Buys 10,500 Shares in Open Market

LENZ Therapeutics Director James W. McCollum purchased 10,500 shares of common stock at a weighted average price of $22.7884.

Summary

• James W. McCollum, a Director of LENZ Therapeutics, Inc. (LENZ), acquired 10,500 shares of common stock.
• The transaction occurred on November 7, 2025, at a weighted average price of $22.7884 per share.
• The purchase price ranged from $22.68 to $22.87 per share.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.
• Following this transaction, Mr. McCollum directly owns 10,500 shares and indirectly owns 620,599 shares through a trust, totaling 631,099 shares beneficially owned.
• The indirect ownership includes 95,034 shares transferred to the McCollum Living Trust on June 6, 2024.

Sentiment

Score: 8

Explanation: The purchase of shares by a director, especially under a 10b5-1 plan, is a strong positive signal of management confidence in the company's value and future prospects.

Positives

• A company director, James W. McCollum, purchased 10,500 shares of common stock, signaling confidence in the company's future prospects.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-arranged, non-opportunistic purchase.

Future Outlook

This filing does not contain specific forward-looking statements or guidance regarding the company's future performance.

Industry Context

Insider buying, particularly by a director, is often viewed by the market as a positive signal, indicating management's belief in the company's undervaluation or strong future prospects. This action by a LENZ Therapeutics director could be interpreted as a sign of confidence in the company's strategic direction or upcoming developments within the biotechnology and pharmaceutical industry.

Corporate Governance

Stakeholder Impact

• Shareholders: The insider purchase may instill greater confidence among existing and potential shareholders, suggesting that a key insider believes the stock is a good investment.
• Employees: May indirectly boost morale by signaling leadership's belief in the company's future.

Key Dates

Recommendation

The purchase of a significant number of shares by a company director, James W. McCollum, at market prices, particularly when executed under a Rule 10b5-1 plan, is a strong indicator of insider confidence. This action suggests that a key member of management believes the company's stock is undervalued or expects positive future developments. Such insider buying often precedes positive stock performance and serves as a compelling signal for investors to consider a 'buy' position, assuming other fundamental analyses align.

Keywords

LENZ Therapeutics, LENZ, Insider Trading, Stock Purchase, Director, Common Stock, Form 4, Rule 10b5-1